These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 15083185)

  • 1. The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients.
    Masuya D; Huang C; Liu D; Nakashima T; Kameyama K; Haba R; Ueno M; Yokomise H
    Br J Cancer; 2004 Apr; 90(8):1555-62. PubMed ID: 15083185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.
    Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ
    Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma.
    Tolnay E; Kuhnen C; Wiethege T; König JE; Voss B; Müller KM
    J Cancer Res Clin Oncol; 1998; 124(6):291-6. PubMed ID: 9692834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiRNA-200a expression is inverse correlation with hepatocyte growth factor expression in stromal fibroblasts and its high expression predicts a good prognosis in patients with non-small cell lung cancer.
    Chen Y; Du M; Wang J; Xing P; Zhang Y; Li F; Lu X
    Oncotarget; 2016 Jul; 7(30):48432-48442. PubMed ID: 27374174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.
    Cascone T; Xu L; Lin HY; Liu W; Tran HT; Liu Y; Howells K; Haddad V; Hanrahan E; Nilsson MB; Cortez MA; Giri U; Kadara H; Saigal B; Park YY; Peng W; Lee JS; Ryan AJ; Jüergensmeier JM; Herbst RS; Wang J; Langley RR; Wistuba II; Lee JJ; Heymach JV
    Clin Cancer Res; 2017 Sep; 23(18):5489-5501. PubMed ID: 28559461
    [No Abstract]   [Full Text] [Related]  

  • 6. [c-Met and HGF expression in non-small-cell lung carcinomas].
    Korobko IV; Zinov'eva MV; Allakhverdiev AK; Zborovskaia IB; Svwrdlov ED
    Mol Gen Mikrobiol Virusol; 2007; (2):18-21. PubMed ID: 17598453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma.
    Edakuni G; Sasatomi E; Satoh T; Tokunaga O; Miyazaki K
    Pathol Int; 2001 Mar; 51(3):172-8. PubMed ID: 11328532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormality of the hepatocyte growth factor/MET pathway in pulmonary adenocarcinogenesis.
    Tachibana K; Minami Y; Shiba-Ishii A; Kano J; Nakazato Y; Sato Y; Goya T; Noguchi M
    Lung Cancer; 2012 Feb; 75(2):181-8. PubMed ID: 21872356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and localization of HGF and met in Wilms' tumours.
    Alami J; Williams BR; Yeger H
    J Pathol; 2002 Jan; 196(1):76-84. PubMed ID: 11748645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocyte growth factor/scatter factor expression and c-met in primary breast cancer.
    Nagy J; Curry GW; Hillan KJ; McKay IC; Mallon E; Purushotham AD; George WD
    Surg Oncol; 1996 Feb; 5(1):15-21. PubMed ID: 8837300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wnt5a expression is associated with the tumor proliferation and the stromal vascular endothelial growth factor--an expression in non-small-cell lung cancer.
    Huang CL; Liu D; Nakano J; Ishikawa S; Kontani K; Yokomise H; Ueno M
    J Clin Oncol; 2005 Dec; 23(34):8765-73. PubMed ID: 16314637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells.
    Navab R; Liu J; Seiden-Long I; Shih W; Li M; Bandarchi B; Chen Y; Lau D; Zu YF; Cescon D; Zhu CQ; Organ S; Ibrahimov E; Ohanessian D; Tsao MS
    Neoplasia; 2009 Dec; 11(12):1292-300. PubMed ID: 20019837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neural-cadherin expression associated with angiogenesis in non-small-cell lung cancer patients.
    Nakashima T; Huang C; Liu D; Kameyama K; Masuya D; Kobayashi S; Kinoshita M; Yokomise H
    Br J Cancer; 2003 Jun; 88(11):1727-33. PubMed ID: 12771988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist.
    Martin TA; Parr C; Davies G; Watkins G; Lane J; Matsumoto K; Nakamura T; Mansel RE; Jiang WG
    Carcinogenesis; 2003 Aug; 24(8):1317-23. PubMed ID: 12807719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the hepatocyte growth factor and c-Met in colon cancer: correlation with clinicopathological features and overall survival.
    Liu Y; Li Q; Zhu L
    Tumori; 2012; 98(1):105-12. PubMed ID: 22495710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of hepatocyte growth factor and its receptor c-Met in human pituitary adenomas.
    Hou XZ; Liu W; Fan HT; Liu B; Pang B; Xin T; Xu SC; Pang Q
    Neuro Oncol; 2010 Aug; 12(8):799-803. PubMed ID: 20200025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in nonsmall cell lung carcinoma patients.
    Masuya D; Huang C; Liu D; Kameyama K; Hayashi E; Yamauchi A; Kobayashi S; Haba R; Yokomise H
    Cancer; 2001 Nov; 92(10):2628-38. PubMed ID: 11745198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of hepatocyte growth factor and c-MET expression in patients with diffuse large B-cell lymphoma.
    Kawano R; Ohshima K; Karube K; Yamaguchi T; Kohno S; Suzumiya J; Kikuchi M; Tamura K
    Br J Haematol; 2004 Nov; 127(3):305-7. PubMed ID: 15491290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical application of biological markers for treatments of resectable non-small-cell lung cancers.
    Huang C; Liu D; Masuya D; Nakashima T; Kameyama K; Ishikawa S; Ueno M; Haba R; Yokomise H
    Br J Cancer; 2005 Apr; 92(7):1231-9. PubMed ID: 15785747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of VEGF-C status in tumour cells and stromal macrophages in non-small cell lung cancer patients.
    Ogawa E; Takenaka K; Yanagihara K; Kurozumi M; Manabe T; Wada H; Tanaka F
    Br J Cancer; 2004 Aug; 91(3):498-503. PubMed ID: 15226767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.